Callan Family Office LLC Invests $396,000 in argenx SE (NASDAQ:ARGX)

Callan Family Office LLC bought a new position in argenx SE (NASDAQ:ARGX) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 644 shares of the company’s stock, valued at approximately $396,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ARGX. Whipplewood Advisors LLC purchased a new position in shares of argenx during the 4th quarter valued at about $37,000. Global Retirement Partners LLC raised its stake in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after acquiring an additional 48 shares during the period. Jones Financial Companies Lllp raised its stake in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares during the period. Venturi Wealth Management LLC purchased a new position in argenx during the fourth quarter valued at approximately $66,000. Finally, Nkcfo LLC bought a new position in shares of argenx in the fourth quarter worth approximately $68,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Trading Down 3.1 %

Shares of NASDAQ:ARGX opened at $594.21 on Monday. The company has a market cap of $36.10 billion, a price-to-earnings ratio of -675.24 and a beta of 0.59. The company has a 50-day moving average price of $641.45 and a 200 day moving average price of $594.49. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. As a group, equities analysts forecast that argenx SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

ARGX has been the topic of several recent analyst reports. William Blair restated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Wedbush reissued an “outperform” rating and set a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. JMP Securities upped their price objective on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Piper Sandler lifted their target price on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Finally, Truist Financial reissued a “buy” rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and a consensus price target of $662.83.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.